Why the study?
Stent-associated complications remain a challenge after DES for ACS, and DCBs are expected to reduce these complications.
Does drug-coated balloon therapy reduce major adverse cardiovascular events and bleeding compared to drug-eluting stents in patients with acute coronary syndrome?
Does drug-coated balloon therapy reduce major adverse cardiovascular events and bleeding compared to drug-eluting stents in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
Drug-coated balloon therapy is an effective alternative to drug-eluting stents in patients with acute coronary syndrome, showing similar 1-year MACE rates but significantly lower bleeding complications, likely due to a shorter required duration of dual antiplatelet therapy.
Background: Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS. Materials and Methods: In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year. Conclusions: DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.
No takes yet. Share an insight, caveat, or question.
Naganawa et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: